Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 20 min ago
Peer-reviewedCC BYPathogens (Basel, Switzerland)

Co-Circulation of ST11-KL30 and ST11-KL64 Carbapenem-Resistant Klebsiella pneumoniae in Urumqi, Xinjiang, China: Molecular Epidemiology, Antimicrobial Resistance, and Virulence

  • Hefei Zha1
  • Qian Shi1
  • Yongxin Li1
  • Chunyan Liu1
  • Xin Zhang1
  1. 1Department of Medical Laboratory, Hospital of /Second Affiliated Hospital of Shihezi University School of Medicine, Urumqi 830002, China; (H.Z.); (Q.S.); (Y.L.); (C.L.)
Read full textPDFDOICite

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) and hypervirulent CRKP (hv-CRKP) are growing global threats with regional heterogeneity. We collected 93 non-duplicate CRKP isolates from a hospital in Urumqi, China, from January to December 2024. Antimicrobial susceptibility was tested using the VITEK 2 system, hypermucoviscosity was assessed by the string test, resistance and virulence genes were detected by polymerase chain reaction (PCR), and clonal lineages were determined by multilocus sequence typing (MLST) and capsular typing. Isolates were mainly from the intensive care unit (ICU) (36.56%) and respiratory department (31.18%), with sputum (51.62%) the predominant specimen type. Resistance rates to most β-lactams exceeded 97%. blaKPC was the predominant carbapenemase gene (94.62%), and hv-CRKP accounted for 54.84% of isolates. Sequence type 11 (ST11) was the dominant clone (89.25%), with K-locus types (KL30) (44 isolates) and KL64 (31 isolates) most common. ST11-KL30 exhibited significantly lower resistance rates to amikacin, gentamicin, trimethoprim-sulfamethoxazole, and tigecycline, and lower blaTEM carriage compared with ST11-KL64 (p < 0.05); it also showed a lower proportion of hv-CRKP and string test positivity. This study is the first to show that ST11-KL30 and ST11-KL64 co-circulate as dominant hv-CRKP-carrying clones in Urumqi, clarifying their resistance and phenotypic differences and providing key data for regional surveillance.

Related

  1. Epidemiology and Antimicrobial Resistance of Klebsiella pneumoniae at a Tertiary Oncology Centre in Astana, Kazakhstan, 2022-2026: A Prospective Longitudinal Surveillance Study
    G. A. Yessenbayeva, I. Y. Mukatova, Y. V. Zholdybayeva +6
    medRxivPreprintCC BY-NC-NDFull textEpidemiology & public healthmedRxiv
  2. L-histidine metabolic reprogramming is associated with imipenem-relebactam resistance in carbapenem-resistant hypervirulent Klebsiella pneumoniae
    Jun Li, Haolan Wang, Yuyao Wang +6
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
  3. Phytochemical screening as an inhibitor of β-lactamases to overcome the carbapenem-resistant of Klebsiella pneumoniae
    Mahir Azmal, Jibon Kumar Paul, Md. Naimul Haque Shohan +6
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  4. Association of Carbapenemase Gene Profiles with Ceftazidime–avibactam Resistance in Carbapenem-Resistant Klebsiella pneumoniae
    Elif Tuğçe Güner, Ayfer Bakır, Cemal Çiçek +1
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General medicineCrossref
  5. Beyond Resistance: Carbapenemase Gene Profiles and Mortality in ICU Patients with Carbapenem-Resistant Klebsiella pneumoniae Infections
    Esra Kaya, Elif Okumuş, Elif Gülsüm Torun
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{zha2026cocirculation,
  title = {{Co-Circulation of ST11-KL30 and ST11-KL64 Carbapenem-Resistant Klebsiella pneumoniae in Urumqi, Xinjiang, China: Molecular Epidemiology, Antimicrobial Resistance, and Virulence}},
  author = {Hefei Zha and Qian Shi and Yongxin Li and Chunyan Liu and Xin Zhang},
  journal = {Pathogens (Basel, Switzerland)},
  year = {2026},
  month = oct,
  doi = {10.3390/pathogens15101089},
  url = {https://europepmc.org/article/PMC/PMC13708353},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Co-Circulation of ST11-KL30 and ST11-KL64 Carbapenem-Resistant Klebsiella pneumoniae in Urumqi, Xinjiang, China: Molecular Epidemiology, Antimicrobial Resistance, and Virulence
AU  - Hefei Zha
AU  - Qian Shi
AU  - Yongxin Li
AU  - Chunyan Liu
AU  - Xin Zhang
PY  - 2026
DA  - 2026/10/01
JO  - Pathogens (Basel, Switzerland)
DO  - 10.3390/pathogens15101089
UR  - https://europepmc.org/article/PMC/PMC13708353
AB  - Carbapenem-resistant Klebsiella pneumoniae (CRKP) and hypervirulent CRKP (hv-CRKP) are growing global threats with regional heterogeneity. We collected 93 non-duplicate CRKP isolates from a hospital in Urumqi, China, from January to December 2024. Antimicrobial susceptibility was tested using the VITEK 2 system, hypermucoviscosity was assessed by the string test, resistance and virulence genes were detected by polymerase chain reaction (PCR), and clonal lineages were determined by multilocus sequence typing (MLST) and capsular typing. Isolates were mainly from the intensive care unit (ICU) (36.56%) and respiratory department (31.18%), with sputum (51.62%) the predominant specimen type. Resistance rates to most β-lactams exceeded 97%. blaKPC was the predominant carbapenemase gene (94.62%), and hv-CRKP accounted for 54.84% of isolates. Sequence type 11 (ST11) was the dominant clone (89.25%), with K-locus types (KL30) (44 isolates) and KL64 (31 isolates) most common. ST11-KL30 exhibited significantly lower resistance rates to amikacin, gentamicin, trimethoprim-sulfamethoxazole, and tigecycline, and lower blaTEM carriage compared with ST11-KL64 (p < 0.05); it also showed a lower proportion of hv-CRKP and string test positivity. This study is the first to show that ST11-KL30 and ST11-KL64 co-circulate as dominant hv-CRKP-carrying clones in Urumqi, clarifying their resistance and phenotypic differences and providing key data for regional surveillance.
SN  - 2076-0817
ER  -